Scarica l'app Stockscreener
701.85
0.90%
-6.40
Dopo l'orario di chiusura:
706.33
4.48
+0.64%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Regeneron advances anticoagulant antibody program - The Pharma Letter
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Principal Financial Group Inc. - MarketBeat
REGNRegeneron Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible - GlobeNewswire
Regeneron Will Move Two Factor XI Agents Into Phase III - Citeline News & Insights
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron reports positive results for two anti-coagulant drugs - Seeking Alpha
Regeneron says study data support big bet on new blood thinners - BioPharma Dive
Cutaneous Squamous Cell Carcinoma Market Set to Grow - openPR
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results - The Manila Times
Regeneron To Advance Two Factor Xi Antibodies Into A Broad Phase 3 Program - XM
Regeneron posts Phase 3 win for Eylea HD in retinal vein occlusion - MSN
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month LowHere's Why - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study - Yahoo Finance
Broader Eylea HD label on the cards after Phase III win - The Pharma Letter
Atopic Dermatitis: A Crowded Field With Room To Grow - Citeline News & Insights
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by Canaccord Genuity Group - MarketBeat
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Regeneron to Present at J.P. Morgan Healthcare Conference 2025: Strategic Updates Expected - StockTitan
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease StudyRegeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga
Regeneron, Bayer Build Retinal Vein Occlusion Case for Eylea as Biosimilar Pressure Mounts - BioSpace
Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Hold Rating from Analysts at Canaccord Genuity Group - MarketBeat
EYLEA HD achieves comparable vision gains with fewer doses - Investing.com
Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
Canaccord Genuity Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Hold Recommendation - MSN
Regeneron, Allele Settle Covid Cocktail Patent Infringement Suit - Bloomberg Law
Allele, Regeneron Settle COVID Treatment Patent Suit - Law360
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year - The Manila Times
Regeneron settles patent lawsuit over protein for testing COVID-19 treatments - Reuters.com
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Galderma’s Nemluvio Brings New Mechanism To Atopic Dermatitis - Citeline
Global EYLEA Drug Market: With CAGR of 7.2% by 20242031 Market - openPR
Lord Abbett & CO. LLC Sells 22,151 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Unloaded Rep. Jonathan L. Jackson - MarketBeat
Regeneron's SWOT analysis: eylea franchise faces challenges as stock navigates pipeline potential - Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week LowTime to Sell? - MarketBeat
Oddo BHF Asset Management Sas Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Wilmington Savings Fund Society FSB Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt? - Simply Wall St
Regeneron stock touches 52-week low at $735 amid market shifts - Investing.com Australia
Regeneron Down 15.5% Year to Date: How to Play the Stock? - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Reduced by Franklin Resources Inc. - MarketBeat
Teachers Retirement System of The State of Kentucky Sells 7,517 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Enters Oversold Territory (REGN) - Nasdaq
Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma - PharmaVoice
Regeneron Fights Sandoz Eylea Patent-Misconduct Claims (Correct) - Bloomberg Tax
Blankinship & Foster LLC Buys New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Pine Valley Investments Ltd Liability Co Has $5.58 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
42,066 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by World Investment Advisors LLC - MarketBeat
Sanctuary Advisors LLC Sells 9,361 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
6,054 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Virtu Financial LLC - MarketBeat
Toronto Dominion Bank Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
(REGN) On The My Stocks Page - Stock Traders Daily
Regeneron reinstated with an Underperform at BofA - Yahoo Finance
Biotech Roundup: 3 Stocks to Watch - Schaeffers Research
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope - Yahoo Finance
AMGN: 3 Biotech Stocks Revolutionizing Cancer Treatment - StockNews.com
Regeneron Pharmaceuticals (REGN): Sales Struggles and Future Prospects - Insider Monkey
Regeneron Pharmaceuticals (NASDAQ:REGN) Receives "Underperform" Rating from Bank of America - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Geode Capital Management LLC - MarketBeat
Vestcor Inc Has $22.70 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
0.16%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):